3:34–4:45 pm Friday, March 8

Chronic Post-Surgical Pain: Which Patients? Why? What Can Be Done? (211)

Chronic post-surgical pain (CPSP) is increasingly recognized as a serious chronic pain entity that is challenging to manage. CPSP often severely affects quality of life, contributes to chronic opioid use and increasing health care costs. This session will examine the epidemiology and pathophysiology of CPSP. We will also address risk factors associated, evidence-based preventative strategies and multimodal approaches that may help prevent or mitigate CPSP.

Epidemiology and Pathophysiology

David Clark

Multimodal Management of Chronic Post-Surgical Pain

Neel D. Mehta, MD

Learning Objectives:

  • Review epidemiology and pathophysiology of CPSP.
  • Review risk factors and preventative strategies including ketamine and lidocaine infusions for CPSP.
  • Discuss evidence-based multimodal approach to management of CPSP.

May L. Chin, MD


David Clark

11 am–Noon Sunday, March 10

Neuropathic Pain Pharmacologic Management: Maximizing Success with Available Agents and Emerging Therapies (411)

Efficacy is often limited with currently available neuropathic pain adjuvants. This session will focus on mitigating the failure of currently available pharmacologic agents, recognizing the limitation of current neuropathic pain algorithms, understanding the role of pharmacogenomics in neuropathic pain treatment choice, and the status of novel agents in development.

Mitigating Neuropathic Pain Pharmacologic Failures

James C. Watson, MD

Emerging Therapies in the Treatment of Neuropathic Pain

Charles E. Argoff, MD

Learning Objectives:

  • Understand common reasons patients fail first line neuropathic pain adjuvants and practical approaches to maximize the chance of success with currently available agents.
  • Understand the limitations of evidence based neuropathic pharmacologic treatment algorithms.
  • Understand where novel or re-emerging treatments fit within current evidence based treatment algorithms.
  • Understand how advances in pharmacogenomics may influence neuropathic pain pharmacologic treatment choices currently and in the future.
9:45 am–10:45 Sunday, March 10

Neuropathic Pain: Beyond Adjuvants and Opioids—A Look at New and Reemerging Treatments (407)

The Role of Low-Dose Naltrexone for the Treatment of Neuropathic Pain Syndromes

Neel D. Mehta, MD

Buprenorphine in Neuropathic Pain Treatment

James C. Watson, MD

Cancer Neuropathic Pain: What's New?

Amitabh Gulati, MD

Learning Objectives:

  • Understand the role of low dosed naltrexone in the treatment of neuropathic pain.
  • Recognize novel treatments in development and emerging evidence for role of currently available or repurposed treatments in the treatment of neuropathic pain.
  • Understand where these novel or re-emerging treatments fit within current evidence based treatment algorithms.
Subscribe to this RSS feed